Multiplex Assay for Detection of Dengue Virus


Dengue virus (DENV) is the cause of dengue illness (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome). CDC researchers have developed a RT-PCR multiplex assay that, prior to sero-conversion, selectively detects dengue virus in biological or other fluid media, such as whole blood, plasma, or serum. The primers and probes from this assay are sufficiently specific to amplify and detect all four DENV serotypes. This FDA-approved technology may provide an improved method for rapid and accurate serotyping of dengue virus in clinical and research settings.

Potential Commercial Applications: Competitive Advantages:
  • Rapid, simple and accurate dengue virus (DENV) serotype identification
  • Diagnostic tool for clinical or research settings
 
  • Increased sensitivity and efficiency compared to current antigen-based assays and single reaction real-time RT-PCR analyses
  • Addresses need for accurate molecular diagnosis of DENV
  • FDA approved technology


Development Stage:
  • In vitro data available
  • In situ data available (on-site)


Inventors:

Jorge Munoz-Jordan (CDC)  ➽ more inventions...

Edgardo Vergne (CDC)  ➽ more inventions...

Gilberto Santiago (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,657,361 issued 2017-05-23
U.S. Pat: 10,563,269 issued 2020-02-18
US Application No. 14/354,972
US Application No. 15/488,946

Publications:
Munoz-Jordan JL, et al. PMID 23632064
Santiago GA, et al. PMID 23875046

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-148-2013-0
Updated: Oct 18, 2013